Aug 27, 2025
29:20
For every 20 shares held, investors received 29. The price per share adjusted from $18.84 to $12.99.
The split itself did not change the total investment value.
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Class A (SZSE:301211) operates in the Pharmaceuticals: major industry.
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Class A company overviewHubei Biocause Heilen Pharmaceutical Co., Ltd. Class A's most recent stock split was on August 27, 2025. It was a 29-for-20 forward split, so shareholders received 29 shares for every 20 they held.
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Class A (SZSE:301211) has split its stock 2 times: a 6-for-5 split on May 31, 2023 and a 29-for-20 split on August 27, 2025.
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Class A has split its stock 2 times. This history records 2 forward splits between May 31, 2023 and August 27, 2025.
A stock split divides each share into more shares and lowers the price per share by the same factor, so the total value of a holding does not change. In Hubei Biocause Heilen Pharmaceutical Co., Ltd. Class A's 29-for-20 split on August 27, 2025, every 20 shares became 29 shares.
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Class A has not announced a new split in our records. Its most recent split was on August 27, 2025, 1 year ago. Companies announce splits in advance, and any new SZSE:301211 split will appear on this page.
Already premium?